Tag: toxicity

Find relevant news articles from other European projects, below:

CARAMBA  EURE-CART  CARAT Network ATECT PROCROP

Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:


Immunotherapy Web Featured Images 84

Scientists create ON-OFF switches to control CAR T cell activity

Scientists at Dana-Farber Cancer Institute and Mass General Cancer Center have created molecular ON-OFF switches to regulate the activity of CAR T cells, a potent form of cell-based immunotherapy that has had dramatic success in treating some advanced cancers, but which pose a significant risk of toxic side effects.

Visit website
onclive

Immunotherapy Expert Puts Fresh Focus on AEs

  Oct 15 2020 Tagged ICI, toxicity

In less than 10 years, immune checkpoint inhibitors (ICIs) have dramatically altered the treatment landscape for patients with metastatic melanoma, helping to drive an improvement in 5-year survival rates from historical levels of less than 10% to more than 50% with some regimens.

Visit website
cell1

Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off...

Human brain mural cells, essential for blood-brain barrier integrity, express CD19 and can then be potential off-tumor target for CD19-directed therapies, including CAR-T cells, suggesting a mechanism for associated neurotoxicity.
Visit website
ecancer

Fundamentals of nanoparticles in cancer immunotherapy and radiotherapy

Dr Selvaraj describes the future developments in this area, where next-generation nanoparticles could be developed to enhance the active targeting of tumour cells, and the compatibility with other anti-cancer therapies.

Visit website
jnccn

Multiorgan Immune-Related Adverse Events During Treatment With Atezolizumab

Immune checkpoint inhibitors (ICIs) commonly target CTLA-4, PD-1, and PD-L1, which promote inhibitory signals on immune effector T cells against cancer cells. Although ICIs have improved outcomes in several cancers, their use is also associated with significant adverse events (AEs), including death.

Visit website
blood cancer journal

Infection during the first year in patients treated with CD19 CAR T cells for di...

CD19-targeted chimeric antigen receptor (CAR) T cell therapy is an effective treatment for diffuse large B cell lymphoma (DLBCL).

Visit website